Janssen Pharmaceutica Nv

Leonard, Kristi A.

Xiaohua Xue

Anne Fourie

David A Kummer

Steven D Goldberg

Craig R Woods

Hariharan Venkatesan

Ronald L Wolin

Rachel T Nishimura

Aihua Wang

Maud J Urbanski

James Patrick Edwards

Kevin Douglas Kreutter

Kristi A Leonard

Umar Maharoof

Kent Barbay

Connor L Martin

Maxwell David Cummings

Virginia M Tanis

Steven P Meduna

Stefan McCarver

Elizabeth G Fennema

Alexander Valdes

Timothy B Rhorer

Christian Gege

Christoph Steeneck

Olaf Kinzel

Kelly J McClure

Gerald Kleymann

Thomas Hoffmann

Douglas Behenna

Steven Loskot

John M Keith

William Moore Jones

Alexander Raymond Rovira

Alec D Lebsack

Charlotte Pooley Deckhut

Wai-Ping Leung

Taraneh Mirzadegan

Joan M Pierce

Deane Gordon

Luke E Hanna

Dougas C Behenna

Kristen Song

Kelly Ganamet

Anne M Fourie

Kelly Lynn Ganamet

Joan Pierce

Kelly Mcclure

Jonathan Blevitt

Alexander Rovira

Amy Strasner

Aimee Rose De Leon-Tabaldo

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazine IL-17 inhibitor compounds

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazines as modulators of IL-17

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Pyridinyl pyrazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, Q, R, R, R, R, A, and Aare defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl pyrazoles as modulators of RORgT

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl thiazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Phenyl substituted pyrazoles as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Alkyl linked quinolinyl modulators of ROR&#x3b3;t

Phenyl linked quinolinyl modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Quinolinyl modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Thiazoles as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:X, A, A, A, A, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Trifluoromethyl alcohols as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:R, R, R, R, A, A, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Amide substituted thiazoles as modulators of RORyt

Growing community of inventors

San Diego, CA, United States of America

Xiaohua Xue